Loading clinical trials...
Loading clinical trials...
PNOC044: Liothyronine (L-T3) in Combination With Bevacizumab, Irinotecan and Temozolomide (BIT) for Progressive or Relapsed Medulloblastoma (Cohort 1) or as Monotherapy for Medulloblastoma With Minimal Residual Disease (Cohort 2)
Conditions
Interventions
Liothyronine (L-T3)
Bevacizumab
+2 more
Locations
1
United States
University of California, San Francisco
San Francisco, California, United States
Start Date
March 1, 2026
Primary Completion Date
March 31, 2031
Completion Date
March 31, 2031
Last Updated
January 16, 2026
NCT05278208
NCT05535166
NCT07087002
NCT06898684
NCT06624371
NCT04501718
Lead Sponsor
Sabine Mueller, MD, PhD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions